Best practices for screening, testing, diagnosing, and treating patients with hepatitis D (delta) virus based on global expert review and recent guidelines
Open Access
- 1 August 2025
- journal article
- review article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 30 (4)
Abstract
Background: Hepatitis D virus (HDV) represents the most severe form of human viral hepatitis, associated with rapid progression to cirrhosis and increased liver-related mortality. Globally, an estimated 9-19 million individuals are anti-HDV positive. To ensure early detetion, current guidelines recommend screening all HBsAg-positive individuals or, at a minimum, those with defined risk factors. Methods: This expert consensus paper updates the current landscape of HDV management. Recommendations were derived from a structured expert panel discussion, incorporating recent evidence and clinical guideline developments, with a focus on screening, diagnosis, and antiviral therapy. Results: The panel emphasized the importance of systematic HDV screening in HBsAg-positive individuals. Therapeutic strategies aim at sustained HDV-RNA suppression and, ideally, HBV surface antigens (HBsAg) loss. Bulevirtide was recommended as a long-term monotherapy. Pegylated interferon alpha (PEG-IFNα), if used, should be limited to 48 weeks and tailored based on viral response and tolerability. Combination therapy with bulevirtide and PEG-IFNα may be considered in selected cases. Conclusion: This consensus provides updated recommendations for the screening, diagnosis, and treatment of HDV infection, highlighting the role of bulevirtide and individualized therapeutic approaches. As the treatment landscape continues to evolve, combination regimens and novel agents currently under investigation may offer additional options in the near future.Keywords
Funding Information
- Gilead Sciences
This publication has 91 references indexed in Scilit:
- A phase 2 dose‐finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitisHepatology, 2021
- Spontaneous Clearance of Chronic Delta HepatitisHepatology, 2020
- Long‐Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver‐Related OutcomesHepatology, 2020
- Hepatitis C Virus Diagnostics: The Road to SimplificationClinical Liver Disease, 2018
- Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B GuidanceClinical Liver Disease, 2018
- Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV‐1 studyHepatology, 2017
- A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus–infected mongoliansHepatology, 2016
- Antiviral treatment and liver‐related complications in hepatitis deltaHepatology, 2016
- First international external quality assessment for hepatitis delta virus RNA quantification in plasmaHepatology, 2016
- Late HDV RNA Relapse After Peginterferon Alpha-Based Therapy of Chronic Hepatitis DeltaHepatology, 2014